Clinical Experience with the Baerveldt 250-mm2 Glaucoma Implant

Darrell WuDunn, Anh-Danh Phan, Louis Cantor, John T. Lind, Arnold Cortes, Bin Wu

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: To report the intermediate-term results of the Baerveldt 250-mm2 Glaucoma Implant for treatment of adult glaucoma. Design: Retrospective, noncomparative, interventional case series. Participants: One hundred eight adult patients (108 eyes) with glaucoma who received a Baerveldt 250-mm2 Glaucoma Implant. Intervention: Implantation of the Baerveldt 250-mm2 Glaucoma Implant. Main Outcome Measures: Intraocular pressure (IOP), visual acuity, number of glaucoma medications, and surgical complications. Success was defined as IOP ≥ 6 mmHg and ≤ 21 mmHg (with or without antiglaucoma medications), without further glaucoma surgery, devastating complication, or loss of light perception attributable to drainage implantation. Results: Mean age was 63.8±16.5 years. Mean postoperative follow-up was 22.8 months (range, 0.2-84.9; interquartile range, 3.9-36.3). Mean preoperative IOP was 36.3±13.0 mmHg, on 2.9±1.1 antiglaucoma medications. The mean postoperative IOP at final visit was 15.8±7.6 mmHg (P<0.0001, paired t test), on 0.8±1.0 antiglaucoma medications (P<0.0001, Wilcoxon test). Kaplan-Meier success rates were 0.92 (6 months, n = 81), 0.88 (12 months, n = 75), 0.84 (18 months, n = 68), and 0.79 (24 months, n = 61). Conclusions: The Baerveldt 250-mm2 Glaucoma Implant provides good intermediate-term success for the treatment of adult refractory glaucoma.

Original languageEnglish
Pages (from-to)766-772
Number of pages7
JournalOphthalmology
Volume113
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Glaucoma
Intraocular Pressure
Visual Acuity
Drainage
Outcome Assessment (Health Care)
Light
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Clinical Experience with the Baerveldt 250-mm2 Glaucoma Implant. / WuDunn, Darrell; Phan, Anh-Danh; Cantor, Louis; Lind, John T.; Cortes, Arnold; Wu, Bin.

In: Ophthalmology, Vol. 113, No. 5, 05.2006, p. 766-772.

Research output: Contribution to journalArticle

WuDunn, D, Phan, A-D, Cantor, L, Lind, JT, Cortes, A & Wu, B 2006, 'Clinical Experience with the Baerveldt 250-mm2 Glaucoma Implant', Ophthalmology, vol. 113, no. 5, pp. 766-772. https://doi.org/10.1016/j.ophtha.2006.01.049
WuDunn, Darrell ; Phan, Anh-Danh ; Cantor, Louis ; Lind, John T. ; Cortes, Arnold ; Wu, Bin. / Clinical Experience with the Baerveldt 250-mm2 Glaucoma Implant. In: Ophthalmology. 2006 ; Vol. 113, No. 5. pp. 766-772.
@article{708294499bef44589fa519954a762b17,
title = "Clinical Experience with the Baerveldt 250-mm2 Glaucoma Implant",
abstract = "Purpose: To report the intermediate-term results of the Baerveldt 250-mm2 Glaucoma Implant for treatment of adult glaucoma. Design: Retrospective, noncomparative, interventional case series. Participants: One hundred eight adult patients (108 eyes) with glaucoma who received a Baerveldt 250-mm2 Glaucoma Implant. Intervention: Implantation of the Baerveldt 250-mm2 Glaucoma Implant. Main Outcome Measures: Intraocular pressure (IOP), visual acuity, number of glaucoma medications, and surgical complications. Success was defined as IOP ≥ 6 mmHg and ≤ 21 mmHg (with or without antiglaucoma medications), without further glaucoma surgery, devastating complication, or loss of light perception attributable to drainage implantation. Results: Mean age was 63.8±16.5 years. Mean postoperative follow-up was 22.8 months (range, 0.2-84.9; interquartile range, 3.9-36.3). Mean preoperative IOP was 36.3±13.0 mmHg, on 2.9±1.1 antiglaucoma medications. The mean postoperative IOP at final visit was 15.8±7.6 mmHg (P<0.0001, paired t test), on 0.8±1.0 antiglaucoma medications (P<0.0001, Wilcoxon test). Kaplan-Meier success rates were 0.92 (6 months, n = 81), 0.88 (12 months, n = 75), 0.84 (18 months, n = 68), and 0.79 (24 months, n = 61). Conclusions: The Baerveldt 250-mm2 Glaucoma Implant provides good intermediate-term success for the treatment of adult refractory glaucoma.",
author = "Darrell WuDunn and Anh-Danh Phan and Louis Cantor and Lind, {John T.} and Arnold Cortes and Bin Wu",
year = "2006",
month = "5",
doi = "10.1016/j.ophtha.2006.01.049",
language = "English",
volume = "113",
pages = "766--772",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Clinical Experience with the Baerveldt 250-mm2 Glaucoma Implant

AU - WuDunn, Darrell

AU - Phan, Anh-Danh

AU - Cantor, Louis

AU - Lind, John T.

AU - Cortes, Arnold

AU - Wu, Bin

PY - 2006/5

Y1 - 2006/5

N2 - Purpose: To report the intermediate-term results of the Baerveldt 250-mm2 Glaucoma Implant for treatment of adult glaucoma. Design: Retrospective, noncomparative, interventional case series. Participants: One hundred eight adult patients (108 eyes) with glaucoma who received a Baerveldt 250-mm2 Glaucoma Implant. Intervention: Implantation of the Baerveldt 250-mm2 Glaucoma Implant. Main Outcome Measures: Intraocular pressure (IOP), visual acuity, number of glaucoma medications, and surgical complications. Success was defined as IOP ≥ 6 mmHg and ≤ 21 mmHg (with or without antiglaucoma medications), without further glaucoma surgery, devastating complication, or loss of light perception attributable to drainage implantation. Results: Mean age was 63.8±16.5 years. Mean postoperative follow-up was 22.8 months (range, 0.2-84.9; interquartile range, 3.9-36.3). Mean preoperative IOP was 36.3±13.0 mmHg, on 2.9±1.1 antiglaucoma medications. The mean postoperative IOP at final visit was 15.8±7.6 mmHg (P<0.0001, paired t test), on 0.8±1.0 antiglaucoma medications (P<0.0001, Wilcoxon test). Kaplan-Meier success rates were 0.92 (6 months, n = 81), 0.88 (12 months, n = 75), 0.84 (18 months, n = 68), and 0.79 (24 months, n = 61). Conclusions: The Baerveldt 250-mm2 Glaucoma Implant provides good intermediate-term success for the treatment of adult refractory glaucoma.

AB - Purpose: To report the intermediate-term results of the Baerveldt 250-mm2 Glaucoma Implant for treatment of adult glaucoma. Design: Retrospective, noncomparative, interventional case series. Participants: One hundred eight adult patients (108 eyes) with glaucoma who received a Baerveldt 250-mm2 Glaucoma Implant. Intervention: Implantation of the Baerveldt 250-mm2 Glaucoma Implant. Main Outcome Measures: Intraocular pressure (IOP), visual acuity, number of glaucoma medications, and surgical complications. Success was defined as IOP ≥ 6 mmHg and ≤ 21 mmHg (with or without antiglaucoma medications), without further glaucoma surgery, devastating complication, or loss of light perception attributable to drainage implantation. Results: Mean age was 63.8±16.5 years. Mean postoperative follow-up was 22.8 months (range, 0.2-84.9; interquartile range, 3.9-36.3). Mean preoperative IOP was 36.3±13.0 mmHg, on 2.9±1.1 antiglaucoma medications. The mean postoperative IOP at final visit was 15.8±7.6 mmHg (P<0.0001, paired t test), on 0.8±1.0 antiglaucoma medications (P<0.0001, Wilcoxon test). Kaplan-Meier success rates were 0.92 (6 months, n = 81), 0.88 (12 months, n = 75), 0.84 (18 months, n = 68), and 0.79 (24 months, n = 61). Conclusions: The Baerveldt 250-mm2 Glaucoma Implant provides good intermediate-term success for the treatment of adult refractory glaucoma.

UR - http://www.scopus.com/inward/record.url?scp=33646152327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646152327&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2006.01.049

DO - 10.1016/j.ophtha.2006.01.049

M3 - Article

VL - 113

SP - 766

EP - 772

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 5

ER -